PHAT — Phathom Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1783183 ·
Last close
$5.50
Market Cap
$447.10M
52W High
$18.31
52W Low
$5.01
ADV30
1,686,848
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 84,722,000 | 66,355,000 | -85,000 | -13,897,000 | 345,020,000 | 184,558,000 | 692,659,000 |
| Jun 2026 | 74,274,000 | 59,178,000 | -3,965,000 | -17,582,000 | 327,075,000 | 182,478,000 | 671,348,000 |
| Mar 2026 | 58,301,000 | 46,305,000 | -15,477,000 | -30,369,000 | 305,120,000 | 180,904,000 | 642,075,000 |
| Dec 2025 | 57,584,000 | 49,936,000 | -5,928,000 | -21,148,000 | 259,149,000 | 129,972,000 | 697,318,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,739,000
Investing CF
$-302,000
Financing CF
$70,445,000
CapEx
$-302,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.03
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,546,106,000
Inventory
$7,632,000
Receivables
$107,602,000
ST Investments
—
EBIT TTM
$-20,290,000
Pretax Income TTM
$-82,996,000
Interest Exp TTM
$62,706,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$274,880,992
EBITDA
$-24,984,000
Free Cash Flow
$-12,944,250
Enterprise Value
$837,505,216
Total Cash
$184,558,000
Total Debt
$555,449,984
Shares Out
81,291,520
Trailing EPS
$-1.26
Book Value
$-4.30
ROE
—
ROA
-5.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 175,110,000 | -159,986,000 | -221,247,000 | 259,149,000 | 697,318,000 | -438,169,000 | -166,775,000 |
| Dec 2024 | 55,252,000 | -277,467,000 | -334,326,000 | 378,318,000 | 631,898,000 | -253,580,000 | -266,770,000 |
| Dec 2023 | 682,000 | -167,312,000 | -201,592,000 | 413,842,000 | 486,601,000 | -72,759,000 | -137,580,000 |
| Dec 2022 | 0 | -172,440,000 | -197,723,000 | 164,810,000 | 239,624,000 | -74,814,000 | -146,530,000 |
TTM Snapshot
Revenues TTM
$239,663,000
NetIncome TTM
$-99,072,000
OpCashFlow TTM
—
Assets (Latest)
$327,075,000
Forward EPS
$1.08
Max Pain — expiry 2028-01-21
max pain strike: $7.50 · spot: $5.30 · call oi: 8,050 · put oi: 187
Expected Move to 2028-01-21:
±$7.43
(140.19%) —
implied range
$-2.13 –
$12.73
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARVN | ARVINAS, INC. | $446.61M | $6.82 | — |
| EOLS | Evolus, Inc. | $442.80M | $6.69 | — |
| INDP | Indaptus Therapeutics, Inc. | $442.36M | $3.32 | — |
| DMAC | DiaMedica Therapeutics Inc. | $452.16M | $8.38 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $437.41M | $6.62 | — |
News headlines (Yahoo Finance, 1h cache)
Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously
2026-11-19 13:00 · Yahoo
Phathom: 3 Key Takeaways for Long-Term Investors
2026-11-18 21:05 · Yahoo
What Comes Next For Phathom Pharmaceuticals After A 65% Slide
2026-11-18 19:06 · Yahoo
Implied Volatility Surging for Phathom Pharmaceuticals Stock Options
2026-11-06 13:00 · Yahoo
What Phathom Pharmaceuticals Bears Spotted Before A 63% Slide
2026-11-04 13:12 · Yahoo
Phathom Pharmaceuticals to Participate in November Investor Conferences
2026-11-04 13:00 · Yahoo
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
2026-11-03 13:00 · Yahoo
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
2026-10-29 21:14 · Yahoo
Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-10-29 21:01 · Yahoo
Phathom (PHAT) Q3 2026 Earnings Call Transcript
2026-10-29 18:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.